A Quick Look at Today's Ratings for Erasca(ERAS.US), With a Forecast Between $4 to $6
Erasca's Promising Developments and Positive Outlook Justify Buy Rating
Goldman Sachs Maintains Buy on Erasca, Lowers Price Target to $3
Erasca Analyst Ratings
HC Wainwright & Co. Maintains Buy on Erasca, Raises Price Target to $6
Erasca Inc. Poised for Growth: Buy Rating Maintained Amidst Promising Trial Updates and Solid Financials
Goldman Sachs Maintains Erasca(ERAS.US) With Buy Rating, Cuts Target Price to $3
Morgan Stanley Maintains Erasca(ERAS.US) With Buy Rating, Cuts Target Price to $4
Morgan Stanley Keeps Their Buy Rating on Erasca (ERAS)
H.C. Wainwright Maintains Erasca(ERAS.US) With Buy Rating, Raises Target Price to $6
Erasca's Innovative Melanoma Treatments Prompt Buy Rating
Goldman Sachs Maintains Buy on Erasca, Lowers Price Target to $4
Goldman Sachs: Maintaining the Erasca (ERAS.US) rating, adjusted from buy to buy rating, and adjusted the target price from $7.00 to $4.00.
Erasca Analyst Ratings
Erasca's Strategic Advances and Financial Fortitude Merit a Buy Rating
HC Wainwright & Co. : Maintain the Erasca (ERAS.US) rating, adjust from buy to buy rating, and adjust the target price from $8.00 to $5.00.
Erasca Analyst Ratings
HC Wainwright & Co. Maintains Buy on Erasca, Lowers Price Target to $5
Erasca's Promising Pipeline and Solid Funding Outlook Balanced by Caution: A Hold Rating
Erasca Inc. Earns Buy Rating: Strategic Acquisitions and Promising Pipeline Positioning
No Data
No Data